Cell Therapy Regulation in Taiwan
On Sept 6, 2018, the Ministry of Health and Welfare (MOHW) issued amendments to the “Administrative Measures for the Implementation or Use of Specific Medical Technology and Inspection, Diagnostic or Medical Devices”. This opens up six areas of cell therapy technology such as autologous immune cell therapy for cancer patients who failed standard treatment and those with terminal cancer; autologous cartilage cell transplantation in the treatment of articular cartilage defects in the knee joint; and autologous transplantation of adipose-derived stem cells in the treatment of extensive burns and chronic wounds. Under the principle of ensuring quality of implementation and protecting rights of patients, medical institutions can submit treatment plans for review and implement them once they are approved, with a requirement for them to produce an implementation results report every year.

MBC has already integrated the corporate’s experience in clinical testing, molecular diagnostics, and construction of large-scale cell manufacturing facility, to establish a complete system that can be used for immune cell therapy research for cancer treatment. We cooperate extensively with medical institutions, aiming to provide patients with high quality technology and services in their treatment.